Effect of spironolactone versus placebo on reducing the risk of atrial fibrillation in patients undergoing coronary artery bypass graft

Effect of spironolactone versus placebo on reducing the risk of atrial fibrillation in patients undergoing coronary artery bypass graft: a single-blind randomized clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N281

Enrollment

130

Registered

2019-05-25

Start date

2019-05-22

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation. Unspecified atrial fibrillation

Interventions

Intervention 1: Intervention group: Routine treatment plus tablet spironolactone 50 mg for 2 weeks. Intervention 2: Control group: Routine treatment plus tablet placebo for 2 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 65 years Candidate for coronary artery bypass graft Ejection fraction more than 30%

Exclusion criteria

Exclusion criteria: Presence of background AF rhythm before the intervention Sensitivity to spironolactone Using amiodarone in the past three months

Design outcomes

Primary

Measure	Time frame
Assessing the risk of atrial fibrillation. Timepoint: 2 weeks after the intervention. Method of measurement: With electrocardiography.;Assessing the ejection fraction. Timepoint: 2 weeks after the intervention. Method of measurement: With echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ava Farzaneh

Hamedan University of Medical Sciences

a.farzanehh@gmail.com+98 81 3838 1740

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026